论文部分内容阅读
美国国立卫生研究院(NIH)将为下列5项研究课题提供700万美元的经费: 呼吸道合胞病毒(RSV)疫苗免疫增强机理:国立变态反应与传染病研究所(NI-AID)将资助100万美元,用于RSV病免疫学研究,以弄清曾接种过福马林灭活RSV疫苗的儿童嗣后感染RSV后病情加剧以及免疫儿童肺炎发病和住院率高于对照组儿童的机理。该课题最终目的是研制一种安全有效的RSV疫苗。 血液组分中病毒的体外灭活:国立心脏、肺和血液研究所(NHLBI)将资助150万美元,用于发现血液组分中病毒的灭活方法。血浆中病毒的灭活技术已获很大成功,然而,灭活全血和血液组分中的病毒则较困难,这主要系由于细胞成分(如浆膜)脆弱性质所致。研究内容包括单克隆抗体的体外中和作用,病毒吸附亲和层析柱,吸收-过滤过程,离心去除法和滤器。
The National Institutes of Health (NIH) will provide $ 7 million for five research topics: Respiratory Syncytial Virus (RSV) Vaccine Immunity Enhancement Mechanism: National Institute of Allergy and Infectious Diseases (NI-AID) to Invest 100 Million US dollars for the RSV immunology study to clarify the children who had been vaccinated with the Formalin-inactivated RSV vaccine subsequently became exacerbated following RSV infection and the mechanism of immunization in children with higher incidence of pneumonia and hospitalization than in the control group. The ultimate goal of this task is to develop a safe and effective RSV vaccine. In Vitro Inactivation of Viruses in Blood Components: The National Heart, Lung and Blood Institute (NHLBI) will fund $ 1.5 million to discover methods of inactivating viruses in blood components. Inactivation of viruses in plasma has been highly successful, however, inactivation of viruses in whole blood and blood components is more difficult due mainly to the fragile nature of cellular components such as serosal membranes. Investigations include in vitro neutralization of monoclonal antibodies, affinity columns for virus adsorption, absorption-filtration processes, centrifugation and filters.